Dual-Targeting Zein Janus Nanoparticles With M2pep Peptide for Glioblastoma Immunotherapy
Ma K, Liu Z, Chai S, Fang Q, Xu R, Zhu W, Liu Y, Zhang T, Guo Z, Cui C, Xu J, Guo S, Chen Y
Summary
Researchers developed M2pep peptide-functionalized Janus nanoparticles (Lf/M2pep@ZEN-DSF) that cross the blood-brain barrier and selectively target M2-polarized tumor-associated macrophages in glioblastoma, repolarizing them to the tumoricidal M1 phenotype. In a 4T1 mouse model, the system achieved 89.7% anti-tumor rate when combined with anti-PD-L1 therapy.
Clinical Significance
Demonstrates how peptide-functionalized nanoparticles can overcome the blood-brain barrier challenge in glioblastoma treatment. The M2pep targeting approach to reprogram immunosuppressive macrophages could inform future peptide-drug conjugate strategies in neuro-oncology.
أبحاث ذات صلة
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…